Golimumab Demonstrates Sustained Efficacy Through 1 Year in Psoriatic Arthritis

Psoriatic Arthritis on Hand
Psoriatic Arthritis on Hand
Intravenous golimumab was effective in reducing the signs and symptoms of active psoriatic arthritis in adult patients with sustained response through 1 year of treatment.

Results from a randomized controlled trial published in Arthritis Care & Research support the efficacy and safety of intravenous golimumab as treatment for psoriatic arthritis (PsA).

Investigators conducted a randomized placebo-controlled trial of 480 adults with PsA. Patients were randomly assigned to receive intravenous golimumab 2 mg/kg (n=241) at weeks 0, 4, and every 8 weeks thereafter or placebo (n=239) at weeks 0, 4, 12, and 20. At week 24, all patients in the placebo group crossed over to receive golimumab 2 mg/kg at weeks 24, 28, and every 8 weeks thereafter; the final study infusions were administered at week 52. Efficacy through week 52 was described as ≥20%, 50%, or 70% improvement in American College of Rheumatology criteria (ACR20/50/70) and ≥75% improvement in Psoriasis Area and Severity Index (PASI75). Radiographic progression was measured using the PsA-modified van der Heijde-Sharp (vdH-S) score. Adverse events were monitored through week 60.

Related Articles

At week 52, 76.8% of patients in the golimumab group and 77.0% in the placebo-crossover group achieved ACR20 response; 58.1% and 53.6%, respectively, achieved an ACR50 response; and 38.6% and 33.9%, respectively, achieved an ACR70 response. In patients with ≥3% body surface area affected, 71.9% in the golimumab group and 60.6% in the placebo-crossover group achieved a PASI75 response at week 52. Mean change from baseline in total vdH-S score was −0.5 in the golimumab group and 0.8 in the placebo-crossover group. At week 52, 42.3% and 33.9% of patients in the golimumab group and the placebo-crossover group, respectively, achieved minimal disease activity.

Through week 60, 50.9% of all golimumab-treatment patients had ≥1 adverse event and 5.2% ≥1 severe adverse event. No opportunistic infections were observed during the trial period, although 2 malignancies and 1 death occurred in golimumab-treated patients.

These data support the efficacy of golimumab, with patients achieving sustained improvements in joint and skin disease over 1 year of treatment. Adverse events during the trial were consistent with existing safety data.


Husni ME, Kavanaugh A, Murphy F, et al. Efficacy and safety of intravenous golimumab through 1 year in patients with active psoriatic arthritis [published online April 12, 2019]. Arthritis Care Res. doi:10.1002/acr.23905